13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

Completed · Phase 2/Phase 3

Conditions studied: Acute Liver Failure

In brief

The ALFSG-MBT protocol is for a multicenter, open label, non-randomized study to determine the value of Breath Identification® (BreathID®) N-(4-Methoxy-13C-phenyl)acetamide (13C-Methacetin) Breath Test System in predicting the outcome of patients diagnosed with severe acute liver injury that is not related to acetaminophen overdose or acute liver failure who meet inclusion/exclusion criteria. Up to 200 evaluable patients will be enrolled. An evaluable patient is one who has completed one or more breath tests for at least 30 minutes after administration of the 13C-Methacetin solution (test substrate). The Breath Test will be performed up to five times during the study period on all enrolled patients. The first Breath Test will be performed upon admission into the study (Day 1) and repeated on Days 2, 3, 5 and 7 provided no contra-indications are present. Each test continuously measures changes in the metabolism of the 13C-Methacetin in order to assess the improvement or deterioration in liver metabolic function about improvement or deterioration in liver metabolic function. If an enrolled non-APAP ALI or ALF patient receives a liver transplant, is discharged /transferred from the hospital or dies prior to Day 7, additional Breath Tests will not be performed. Patients will be contacted for the Day 21 follow up (21 days after enrollment into the trial) to determine spontaneous survival, transplantation and occurrence of serious adverse events since the patient's last study treatment.

Key facts

Study ID

NCT02786836

Run by

University of Texas Southwestern Medical Center

People needed

76

Starts

2016-06-10

Expected to finish

2019-09-18

Last updated by the study team

2020-12-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult men or women (18-80 years of age)
• Severe acute liver injury not related to acetaminophen overdose: INR ≥2.0; no evidence of HE
• Acute liver failure: INR ≥1.5; presence of any degree of HE
• Duration of illness <26 weeks
• Enrolled into the ALFSG Registry.
• Written informed consent from the patient or patient's legally authorized representative or family member as defined in the Federal Register Number 21 Congressional Federal Register (CFR)50.3(m)

You may not qualify if…

• Evidence of pre-existing chronic liver disease
• Pre-existing New York Heart Association stage III/IV heart failure
• Evidence of pre-existing chronic renal failure
• Chronic hemodialysis prior to hospital admission
• Evidence of cirrhosis (unless clinically acute Wilson disease or autoimmune non-APAP ALI or ALF)
• Severe obstructive lung disease (FEV1 <50% of predicted on previous spirometry)
• Severe shock, defined as mean arterial pressure (MAP) <70 mmHg despite >15 µg/kg/min dopamine, >0.1 µg/kg/min epinephrine, or >0.1 norepinephrine µg/kg/min
• Extensive small bowel resection (>50 cm)
• Any evidence of upper GI bleeding at enrollment requiring intervention (endoscopy or red blood cell (RBC) transfusion specifically for upper GI bleeding)
• Liver transplantation (LT) prior to enrollment. (Note: Listing for LT does not preclude participation in the trial.)
• Pregnancy or breastfeeding women (Note: Pregnancy related non-APAP ALI or ALF may be considered for entry following the delivery of the baby and assuming the mother does not wish to breastfeed or collect breast milk during the study period.)
• Allergic to acetaminophen (such as Tylenol® or any other acetaminophen-containing medications)
• Participation in other clinical studies evaluating other experimental treatments or procedures. (Note: Participation in observatory studies is not an exclusion.)
• Patients in whom enteral drugs or fluids are contra-indicated or the patient either does not have an appropriately placed naso-enteric/orogastric tube in situ or cannot tolerate taking the drug preparation orally (200 ml)
• Budd-Chiari Syndrome
• Non-APAP ALI or ALF caused by malignancy
• Moderate and severe adult respiratory distress syndrome (ARDS), as defined by Berlin Criteria.
• Subjects who have received amiodarone in the 30 days prior to study enrollment
• Consumption of any food or beverage that contains caffeine in the 24 hours prior to enrollment
• Consumption of any of the following drugs that may interfere with the metabolism of 13C-Methacetin in the 48 hours prior to study enrollment including: allopurinol, carbamazepine, cimetidine, ciprofloxacin, daidzein, disulfiram, Echinacea, enoxacin, fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or oral contraceptives
• Consumption of alcohol in the 24 hours prior to enrollment
• Smoking cigarettes in the 8 hours prior to enrollment.

Where it is running

• University of Alabama, Birmingham — Birmingham, Alabama, United States
• University of California, San Francisco — San Francisco, California, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Northwestern University — Chicago, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Ohio State University Medical Center — Columbus, Ohio, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• UT Southwestern Medical Center at Dallas — Dallas, Texas, United States
• VCU Medical Center — Richmond, Virginia, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.